Edition:
United States

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

13.08USD
19 Oct 2018
Change (% chg)

$0.30 (+2.35%)
Prev Close
$12.78
Open
$13.00
Day's High
$13.82
Day's Low
$12.80
Volume
195,066
Avg. Vol
199,546
52-wk High
$31.42
52-wk Low
$6.99

Chart for

About

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and... (more)

Overall

Beta: --
Market Cap(Mil.): $1,130.87
Shares Outstanding(Mil.): 41.59
Dividend: --
Yield (%): --

Financials

  DERM.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -2.65 -- --
ROI: -21.03 0.21 14.27
ROE: -31.39 1.17 15.99

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.

Jun 29 2018

UPDATE 2-FDA approves Dermira's wipe for excessive armpit sweating

* Qbrexza expected to launch in October (Adds analyst comment, estimates; updates share move)

Jun 29 2018

Dermira's treatment for excessive armpit sweating gets U.S. approval

June 29 The U.S. Food and Drug Administration on Friday approved Dermira Inc's treatment for excessive armpit sweating, providing patients with an easy-to-use treatment option for an often embarrassing condition.

Jun 29 2018

BRIEF-Dermira Says Company's COO Position Was Eliminated

* DERMIRA SAYS COMPANY'S CHIEF OPERATING OFFICER POSITION WAS ELIMINATED, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source : https://bit.ly/2Iesp3E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 03 2018

BRIEF-Dermira Inc Q1 Loss Per Share $1.42

* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 03 2018

Earnings vs. Estimates